Schreiner MediPharm develops clinical trial label

Schreiner MediPharm has developed a label with light protection that at the same time blinds the drug a for a current clinical trial by WuXi XDC of a novel antibody drug conjugate (ADC).

WuXi XDC is a leading contract research, development and manufacturing organization (CRDMO) headquartered in China with a focus on the global ADC and bioconjugate market.

To support a biotech company in a clinical trial for an ADC drug, WuXi XDC required a reliable label. The light-sensitive active ingredient is filled into vials as a lyophilized powder and must be effectively protected against external influences. WuXi XDC found the most suitable product through the cooperation with Schreiner MediPharm by implementing a light-protect-label that meets the specific customer requirements.

Schreiner MediPharm developed a label with integrated UV and light protection that is perfectly suited for transparent vials. The opaque label completely wraps around the container and offers optimal light protection. At the same time, it supports a dependable and safe conduct of the clinical trial by reliably blinding the investigational drugs. A resealable inspection window enables an unadulterated view of the vial content. That is crucial for inspecting the condition and color of the reconstituted lyophilizate before it is administered and to thus ensure the efficacy of the medication.

The label was customized to suit the specific application and respective container. Hence WuXi XDC benefits from an efficient, multifunctional product combining protection of the light-sensitive active ingredient with reliable blinding as part of a clinical trial. This optimizes processes, accelerates clinical trial workflow, and supports product and patient safety. 

The light protection from Schreiner MediPharm proves to be particularly forward-looking because it is perfectly suited for use in antibody drug conjugates like the one in this trial. ADCs are an important innovation in cancer therapy. Through targeted delivery of drugs into specific tumor cells they enable gentler and more effective treatment compared to conventional chemotherapies. This technology acts directly on the cancer cell, thus largely sparing healthy cells and minimizing side effects.